NIR-PIT exploiting anti-CD44 and anti-CD25 antibodies significantly inhibits tumor growth and prolongs survival in several tumor animal models compared with NIR-PIT based on a single target, owing to the depletion of both cancer cells and immunosuppressive cells in the TME 83. Here, CD44 is linked to cancer.